Identifying Drug Repurposing Candidates for CLN3 Targeting Proteomics Expression Profile

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Juvenile Neuronal Ceroid Lipofuscinosis (CLN3) is a rare, inherited neurodegenerative disease with no effective treatments.
• The lack of therapies necessitates novel approaches for CLN3 treatment.

Purpose of the Study:

• To develop a drug repurposing strategy for CLN3 therapeutics.
• To identify existing FDA-approved drugs that could potentially treat CLN3.

Main Methods:

• Constructed a CLN3 protein expression profile (CPEP) from proteomics data.
• Queried the iLINCS database with CPEP to find drugs with reversal effects.
• Prioritized drug candidates based on regulation strength, coverage, and blood-brain barrier permeability.

Main Results:

• Identified 60 FDA-approved drugs capable of reversing the CLN3 CPEP.
• Vorinostat and Cyclosporine emerged as top candidates due to strong regulation and blood-brain barrier penetration.
• The study successfully generated a prioritized list of potential CLN3 therapeutic agents.

Conclusions:

• Drug repurposing offers a viable strategy for discovering CLN3 treatments.
• Vorinostat and Cyclosporine warrant further investigation as potential CLN3 therapies.
• This approach provides a foundation for developing novel therapeutic interventions for CLN3.